Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 22, 2003 Jeff Hwang	Pfizer Stuffs Its Pipeline Pfizer extends its reach in cardiovascular disease with Esperion Therapeutics.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
BusinessWeek September 5, 2005 Gene G. Marcial	AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer.
The Motley Fool August 30, 2005 Charly Travers	A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note.
BusinessWeek February 9, 2004 Gene G. Marcial	Telik's Promising Tumor Treatments Telik, which develops drugs for cancer -- mainly chemotherapy-resistant solid tumors -- and diabetes may be the next biotech buyout. So says Mark Monane of investment outfit Needham, who identified Esperion Therapeutics in early December as buyout bait.
BusinessWeek March 11, 2010 Ellen Gibson	The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool January 27, 2004 David Nierengarten	Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool August 2, 2004 Brian Gorman	Will Lipitor's Certification Boost Pfizer? The FDA's ruling may help the company ward off a new threat.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
BusinessWeek February 13, 2006 Gene G. Marcial	Apoplexy: Renovis Takes Aim Renovis, a young biopharma developing treatments for pain, trauma, and stroke, could be joining the big leagues.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
BusinessWeek November 27, 2006 Gene G. Marcial	ISIS Takes Heart From A Promising Drug ISIS Pharmaceuticals is a name to watch in the lucrative arena of cholesterol reduction.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear Rebuttal Generic competition for Lipitor is just the beginning. Faith is nice in terms of religion, but when it comes to investments, investors need to be able to make some reasonable assumptions about future growth plans.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
Pharmaceutical Executive October 1, 2006 Rob Scott	Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug."
BusinessWeek December 11, 2006 Gene G. Marcial	Two Allos Drugs Are Taking Aim At Cancer Allos Therapeutics is the next biotech to watch.
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
BusinessWeek October 6, 2003 Gene G. Marcial	Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
Chemistry World January 27, 2009 Matt Wilkinson	Pfizer's Wyeth injection Pfizer has agreed to pay $68 billion ( 48.3 billion) for rival US biopharmaceutical firm Wyeth, gaining access to its rich product portfolio and promising pipeline of experimental drugs.